It was the aim of the study to examine the efficacy of silver coated prostheses in comparison to Rifampin impregnated prostheses in the prevention of vascular graft infections. Material and methods: 24 C3H/HcN mice with a bodyweight between 24 and 27 grams were assigned to four different groups. Group I: control gel-sealed Dacron graft (Uni-Graft®DV) (6), group II: gel-sealed Dacron graft (Uni-Graft®DV) contaminated locally with 2 × 107 CFU/0.2ml Staphylococcus aureus ATCC25923 (6), group III: silver prosthesis (Intergard® Silver) contaminated locally with 2 × 107 CFU/0.2 ml Staphylococcus aureus ATCC 25923 (6), group IV: Rifampin impregnated prosthesis contaminated locally with 2 × 107 CFU/0.2 ml Staphylococcus aureus ATCC 25923 (6). 14 days after primary operation all animals were euthanized and the grafts harvested. Specimens were examined for signs of infections by histology and microbiology. Results: At termination of the trial on day 14 none of the grafts of group 1 were contamined. 6 out of 6 grafts in group 11, 6 out of 6 in group III and 1 out of 6 in group IV presented with infected grafts. The use of the antimicrobial Rifampin could significantly prevent infection after bacterial challenge in group IV. Conclusion: The silver protected prosthesis (Intergard®Silver) seems to be not effective in protecting vascular infection in vivo. However, the Rifampin group showed excellent results. In conclusion Rifampin bonded gelatin-sealed Dacron grafts are significantly more resistant to bacteremic infection than are silver/collagen-coated Dacron grafts.
|Translated title of the contribution||Experimental examination concerning the efficacy of silver-coated dacron prostheses in vascular graft infections following subcutaneous implantation in a standardized infection model|
|Number of pages||6|
|Journal||Zentralblatt fur Chirurgie|
|Publication status||Published - 1 Mar 2003|
- Antiseptic agents
- Standardized infection model
- Vascular graft infection